Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$9.69 -0.04 (-0.41%)
As of 03:59 PM Eastern

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Key Stats

Today's Range
$9.46
$9.72
50-Day Range
$9.12
$9.93
52-Week Range
$8.37
$13.14
Volume
83,023 shs
Average Volume
229,499 shs
Market Capitalization
N/A
P/E Ratio
57.00
Dividend Yield
3.61%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

A cyclist rides past outside the Beijing No
Chinese court sentences a Japanese man to more than 3 years in prison on espionage charges
A Japanese man has been sentenced to three and a half years in prison in China on espionage charges...
This Could Be the Most Profitable Season of Your Life
Institutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the same point in every cycle when crypto enters its most explosive phase — and two experts are showing how to ride it. Inside The Crypto Code Workshop, you’ll get their step-by-step system and $10 in free Bitcoin for attending.
ALPMY Astellas Pharma Inc. - Seeking Alpha
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $9.66 on January 1st, 2025. Since then, ALPMY stock has increased by 0.3% and is now trading at $9.69.

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its quarterly earnings data on Friday, April, 25th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.12. The company earned $3.22 billion during the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a trailing twelve-month return on equity of 16.55% and a net margin of 2.65%.

Shares of Astellas Pharma split on the morning of Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/25/2025
Today
7/18/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
CIK
1446390
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

EPS (Trailing Twelve Months)
$0.17
Trailing P/E Ratio
57.00
Forward P/E Ratio
23.07
P/E Growth
N/A
Net Income
$334.93 million
Net Margins
2.65%
Pretax Margin
1.63%
Return on Equity
16.55%
Return on Assets
7.35%

Debt

Debt-to-Equity Ratio
0.37
Current Ratio
1.13
Quick Ratio
0.85

Sales & Book Value

Annual Sales
$12.56 billion
Price / Sales
N/A
Cash Flow
$1.81 per share
Price / Cash Flow
5.36
Book Value
$5.52 per share
Price / Book
1.76

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.23

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners